Androgenetic alopecia is the most common form of hair loss characterised by a gradual, quantitative and qualitative reduction of the hair on the scalp resulting in thinning and ultimately in their loss.

Androgenetic alopecia affects 60% of men from the age 50 and up and 35% of women until the age of 50.

Men suffering from androgenetic alopecia may start manifesting hair loss from their 20s or even from puberty, with main symptom the retreat of the hair line and the gradual loss from the top of head and the sides .

On the contrary women suffering from it do not manifest visible thinning before their 40s (most of them manifest it after menopause), while the thinning affects the whole of the scalp with focus on the top.

Factors that affect the causes of androgenetic alopecia in men and women are androgens, heredity and age.

A special part plays the reaction of the immune system.

The main medication administered in the last years for the treatment of androgenetic alopecia or its prevention are local or systemic or both.

For men they are finasteride, tretinoin, corticosteroids, minoxidil, η Dutasteride and β-Sitosterol.

In women, besides the above χορηγούνται και τα estrogens, progesterone and its derivatives, cyproterone, spironolactone, cimetidine, diazoxide, viprostole, flutamide and cyclosporin.

Whatever medication is chosen it must be taken daily for at least 6-12-months with monitoring by a dermatologist.

After that, its less frequent application or administration is necessary to maintain the positive results, because the interruption of the use causes the restoration on the scalp of the previous condition.